Chymopapain

DB06752ApprovedWithdrawnProtein Based Therapies

Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest. It... It is an extracellular plant cysteine proteinase similar to papain in specificity.

Mechanism: Chymopapain is thought to degrade proteoglycan content of the intervertebral disc causing loss of glycosaminoglycan and water. This effect will cause the shrinkage of the disc and a reduction of the pressure on the nerve root.
Curator reviewed · 1 reference
Primary indication: Chymopapain is indicated for the development of chemonucleolysis which is used for the digestion of the nucleus pulposus in patients with disc herniation confirmed by myelography.Curator reviewed
Formula / weight: 27000.0 Da
First approval: Canada, 1996
Code names: BAX-1526

Resolves to

Compound

UNII1UK146T40NCAS9001-09-6ChEMBLCHEMBL1201626

Clinical / RWD

RxNorm2525ATCM09AB01

Targets

P13727PRG2

What you can answer from here — as of January 17, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Marketed productAcross 1 country and 1 labeller

1ATC codeIncluding every combination product, plus 8 drug categories

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Chymopapain, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account